NCT00842894View on ClinicalTrials.gov

Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia

CompletedOBSERVATIONAL
Enrollment

3,421

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin detemir

Safety and effectiveness data collection in connection with the use of the drug.

DRUG

biphasic insulin aspart 30

Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.

Trial Locations (1)

MK-1000

Skopje

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00842894 - Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia | Biotech Hunter | Biotech Hunter